Company Overview
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Recent Developments
- Dec 2025 Revenue of $62.90M (+699.0% YoY); net profit $-204.63M.
- Trailing 12 Months Year-on-year growth — revenue +2598.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 2,598.70% |
Stock Price Performance
| 1 Year: | +175.70% |
| 6 Months: | -8.67% |
| 3 Months: | +21.65% |
| 1 Month: | +19.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.72 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 38.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NUVB Nuvation Bio Inc. R2K | 5.90 | -13.72 | $2.05B | 0.00% | -41.57% | -39.51% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1.44M | 727.00K | 3.08M | 4.83M | 13.12M | 83.23M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 88.00K | -788.00K | 990.00K | 2.26M | 9.77M | - |
| Operating Income | -9.22M | -9.02M | -11.55M | -20.48M | -20.43M | -22.79M | -28.19M | -37.87M | -29.34M | -26.52M | -26.13M | -26.34M | -20.20M | -470.38M | -48.10M | -59.00M | -63.59M | -56.43M | 3.88M |
| Net Income | -8.75M | -8.60M | -11.03M | -20.40M | -19.33M | -21.98M | -21.29M | -34.86M | -27.20M | -21.73M | -20.64M | -19.65M | -14.79M | -462.49M | -41.21M | -53.24M | -59.01M | -55.79M | 5.40M |
| Diluted EPS | - | - | - | - | -0.09 | -0.11 | -0.10 | -0.16 | -0.12 | -0.10 | -0.09 | -0.09 | -0.07 | -1.89 | -0.15 | -0.16 | -0.17 | -0.16 | 0.01 |
| R&D Expense | 7.29M | 7.34M | 8.63M | 15.88M | 14.03M | 17.12M | 20.73M | 28.92M | 21.29M | 18.79M | 18.59M | 18.56M | 12.84M | 29.25M | 27.73M | 24.60M | 27.36M | 28.85M | 35.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 7.87M | 62.90M |
| Gross Profit | - | - | - | 0 | 795.00K | - |
| Operating Income | -43.55M | -93.32M | -119.73M | -99.82M | -592.63M | -213.06M |
| Net Income | -41.66M | -86.85M | -104.20M | -75.80M | -567.94M | -204.63M |
| Diluted EPS | - | -0.44 | -0.48 | -0.35 | -2.11 | -0.60 |
| R&D Expense | 32.60M | 69.04M | 87.81M | 71.29M | 99.12M | 115.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Apr 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 221.79M | - | 672.14M | 621.48M | 540.63M | 594.82M |
| Current Assets | - | - | - | - | 667.32M | 616.43M | 526.25M | 571.52M |
| Cash & Equivalents | - | 0 | 29.75M | - | 101.10M | 42.65M | 35.72M | 164.09M |
| Inventory | - | - | - | - | - | - | 0 | 11.41M |
| Receivables | - | - | - | - | - | 0 | 12.72M | 16.08M |
| Total Liabilities | - | - | 6.71M | - | 17.07M | 16.36M | 76.84M | 289.11M |
| Current Liabilities | - | - | 6.55M | - | 13.16M | 13.97M | 58.24M | 82.23M |
| Long Term Debt | - | - | - | - | - | - | - | 47.21M |
| Total Debt | - | - | - | - | 4.26M | 4.01M | 8.91M | 57.35M |
| Total Equity | 117.75M | 0 | 215.08M | - | 655.08M | 605.12M | 463.79M | 305.72M |
| Shares Outstanding | - | - | - | - | 218.63M | 219.05M | 337.84M | 346.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.53M | -68.19M | -96.11M | -68.00M | -130.41M | -173.43M |
| Investing Cash Flow | -70.32M | -454.67M | 63.46M | 8.92M | 122.70M | 99.52M |
| Financing Cash Flow | 133.13M | 625.53M | 1.33M | 628.00K | 331.00K | 202.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 10.1% | - |
| Operating Margin % | - | - | - | - | -7,527.3% | -338.7% |
| Net Margin % | - | - | - | - | -7,213.8% | -325.3% |
| ROE % | -19.4% | - | -15.9% | -12.5% | -122.5% | -66.9% |
| ROCE % | -20.2% | - | -18.2% | -16.4% | -122.9% | -41.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.93% | 51.99M | $305.96M |
| 2 | Decheng Capital LLC | 7.45% | 25.95M | $152.74M |
| 3 | Blackrock Inc. | 7.21% | 25.10M | $147.72M |
| 4 | Vanguard Capital Management LLC | 3.34% | 11.63M | $68.42M |
| 5 | Omega Fund Management, Llc | 2.32% | 8.08M | $47.56M |
| 6 | Laurion Capital Management, LP | 2.25% | 7.82M | $46.04M |
| 7 | State Street Corporation | 1.95% | 6.78M | $39.93M |
| 8 | Geode Capital Management, LLC | 1.68% | 5.86M | $34.51M |
| 9 | Duquesne Family Office Llc | 1.30% | 4.54M | $26.72M |
| 10 | Bank of America Corporation | 0.92% | 3.22M | $18.95M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NUVB
Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOcFBVVi1URkdvVmh0eGRWWUNYX1puemJTWnk4dEVza1JFS0xFREZnOEEwSUpYYnM5bkM3RElzVzRvb1NwVFdsQTlERzVNQ2QweldrM1hpaklrSVlsbGdNZFBBZG9XbTJCYlZINXRzS1pBMDdnRDdPTWxJeFdFclZBSHVaa2dCQXgtYXl3M3…
$NUVB stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQWEhrSHZ1WmJGWjZsdGMxXy1Za3p1X2x2TW8tZS04OGJkLU9OTjZhQ0FSa0swWC1pYVBkcUJ0aXVMSVpDTS1kM2RPREc5bGdXY1ZkY3pOMk1BeHBLcHhTdnNmVklUY09fcHpPS0VQVEVGMS03WnM3UkphaHpTMEpkVDloTF9VSWMyNzRDZ2…
Is Nuvation Bio (NUVB) Fairly Valued Following UK Taletrectinib Filing Progress? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZUtucnVyVjl6d2xLYm1iN3d3REtXZVhOWHVhR1lKaFZTVlZCV0g0QTl1LU1Ia2FkMkpySS14MjNYY0I0cjB2V1NSRG1yWEZPVlpxeFFZVmktb09DX3gybVA1YnFxZHh3bl9mWllyMDZPX0lRRVZ6Ukl3MC1sOGowa1BMWFE4cExWZ0ZNb2…
RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPYlhzWHNLSkNucGJrb0ZONXhNZW1EVm13Y1kxSFo0c1U5OXdNLXd2bklIRW9hLVpWSHUzeU5nejB1UnFSV3lmdVNWM21ZdUhvcURjcy1HTnc5aGNXNjAySjVubnFmT1g3bVR0QUxnZzlWbTZvY3Y4Y3ZXZ3hZZ0RlS1d3TQ?oc=5" targe…
NUVB Stock Builds Momentum As Charts And Cash Position Strengthen - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1YZXJ6bXRPbW9jSTNaU0hMdk9xQ3ZpYV9HUERXWUNXRUs4UFFlM3BqcFdVWnlnTFI1bzV2U2F2bUJxX3Nvb2NRQVV0ek0wVkRNWmtvcVFteGtESXlGbGdrcmVaM1ZwMjV4LWdodElrdXdFMy1Gckc1cw?oc=5" target="_blank">NUVB …
Nuvation Bio Announces Proposed Convertible Senior Notes Offering - PR Newswire
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNVkROVXlyNi1lUmFYUlo4VVhsRHJUUHJSQjkxMGUyVzlsNVYtcDJ2ekRkZWxzQ254bTIwZzFFT205c3dmQ2U3MUpHVmdybDRTWkctaXY4SktmS2tmZ2tEZ3QzemxDa090OFZrZC11N09vQy1EVHp3ZVJuTmVZLVlfazkzNkZkUWNsNTNvMU…
NUVB — Frequently Asked Questions
What is the current share price of Nuvation Bio Inc. (NUVB)?
As of 2026-07-15 16:51 PDT, Nuvation Bio Inc. (NUVB) trades at $5.90 on NYSE. Its 52-week range is $2.13 to $9.54.
What is the market capitalisation of NUVB?
Nuvation Bio Inc. (NUVB) has a market capitalisation of $2.05B on NYSE.
What is the P/E ratio of NUVB?
NUVB trades at a trailing price-to-earnings (P/E) ratio of -13.72. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 6.40.
What is the return on equity (ROE) of NUVB?
NUVB has a return on equity (ROE) of -39.51%. Its return on capital employed (ROCE) is -41.57%.
Is NUVB a good stock to buy?
This page provides a data-driven analysis of Nuvation Bio Inc. (NUVB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.